Artificial Intelligence (AI) is reshaping the pharmaceutical industry, ushering in a new era of innovation, performance, and patient-centric care. From early-stage drug discovery to post-market surveillance, AI is emerging as a transformative force throughout the drug development lifecycle. But beyond automation and cost efficiency, how exactly is AI delivering strategic value to pharma and biotech companies and how can it redefine the future of healthcare?

Import tariffs are playing an increasingly pivotal role in international economic policy, especially as geopolitical tensions intensify. Once primarily aimed at shielding local industries, tariffs are now also used as strategic tools in wider policy discussions. The renewed focus on tariff measures could have enduring consequences for global supply chains, business and consumer sentiment, and overall economic performance – shaping both corporate operations and valuation models.

We are presenting the inaugural edition of the Iceberg Index© Report, a groundbreaking performance indicator that sheds light on the unseen aspects of corporate value.

The pharmaceutical CDMO sector in Europe is rapidly evolving, driven by growing demand for specialized drug development, manufacturing, and packaging services. As therapies become more complex, CDMOs must invest in expertise, advanced infrastructure, and cutting-edge technologies to stay competitive.

A year after the first White Paper, by Eight Advisory, our international arm, political momentum has accelerated, but investment standards remain a major hurdle. While Eastern Europe ramps up unprecedented defence commitments, investors are still steering clear of the sector. The question is: how do we mobilise capital to support Europe’s security ambitions?

As part of Eight International, McGrathNicol and DH Advisory will support other member firms and their clients on Australian and Middle East-related matters, whilst being able to offer a truly international offering to its clients.

We are a truly global independent organisation of more than 3600 Transactions, Restructuring and Operational Transformation experts, including over 160 partners in more than 30 countries

Independence frees us from any conflict of interest
and allows us to guarantee confidentiality

We Take Your Challenges As Our Own
With Dedication And Commitment

We Solve Problems, Not Provide Services And Strive To Understand Your Unique Challenges
Via A Personalised And ‘Human’ Approach